Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
给药顺序的疗效:Sacituzumab Govitecan 和 Trastuzumab Deruxtecan 治疗 HER2 低表达转移性乳腺癌
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-024-02766-9
Poumeaud, F; Morisseau, M; Cabel, L; Gonçalves, A; Rivier, C; Trédan, O; Volant, E; Frenel, J-S; Ladoire, S; Jacot, W; Jamelot, M; Foka Tichoue, H; Patsouris, A; Teixeira, L; Bidard, F-C; Loirat, D; Brunet, M; Levy, C; Bailleux, C; Cabarrou, B; Deleuze, A; Uwer, L; Deluche, E; Grellety, T; Franchet, C; Fiteni, F; Bischoff, H; Vion, R; Pagliuca, M; Verret, B; Bécourt, S; Reverdy, T; de Nonneville, A; Dalenc, F